TY - JOUR T1 - Impact of persistent D-Dimer elevation following recovery from COVID-19 JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.OA90 VL - 58 IS - suppl 65 SP - OA90 AU - Antje Lehmann AU - Helmut Prosch AU - Sonja Zehetmayer AU - Maximilian Robert Gysan AU - Marco Idzko AU - Daniela Gompelmann Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/OA90.abstract N2 - Elevated D-dimer is known as predictor for severity of SARS-CoV2-infection. Thereby, elevated D-dimer is associated with thromboembolic complications, but it is also a direct consequence of the acute lung injury seen in COVID-19 pneumonia.To evaluate the rate of persistent elevated D-dimer and its association with thromboembolic complications and persistent ground glass opacities (GGO) after recovery from COVID-19.In this post hoc analysis of a prospective multicenter trial, patients underwent blood sampling, measurement of diffusion capacity, blood gas analysis and multidetector computed tomography (MDCT) scan following COVID-19. In case of increased D-dimer (>0,5 µg/ml), an additional contrast medium-enhanced CT was performed in absence of contraindications. Results were compared between patients with persistent D-dimer elevation and patients with normal D-dimer.129 patients (median age 48.8 years; range 19-91 years) underwent D-Dimer assessment after a median (IQR) of 94 days (64-130) following COVID-19. D-dimer elevation was found in 15% (19/129) and was significantly more common in patients who had experienced a severe SARS-CoV2 infection that had required hospitalisation compared to patients with mild disease (p=0.049). Contrast-medium CT (n=15) revealed an acute pulmonary embolism in one and CTEPH in another patient. A significant lower mean pO2 (p=0.015) and AaDO2 (p=0.043) were observed in patients with persistent D-Dimer elevation, but the rate of GGO were similar in both patient groups (p=0.33)In 15% of the patients recovered from COVID-19, persistent D-dimer elevation was observed after a median of 3 months following COVID-19. Those had a more severe COVID and still a lower mean pO2 and AaDO2.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA90.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -